* Allogene Therapeutics Inc reported a quarterly adjusted loss of 32 cents​​ per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of -37 cents. The mean expectation of seventeen analysts for the quarter was for a loss of 33 cents per share. Wall Street expected results to range from -39 cents to -29 cents per share.

* Reported revenue was zero​; analysts expected $12.93 thousand.

* Allogene Therapeutics Inc's reported EPS for the quarter was a loss of 32 cents​.

* The company reported a quarterly loss of $66.29 million.

* Allogene Therapeutics Inc shares had risen by 13.9% this quarter and lost 0.6% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had fallen by about 0.7% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Allogene Therapeutics Inc is 9.50 This summary was machine generated from LSEG data November 8 at 05:16 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.33 -0.32 Beat

Jun. 30 2024 -0.35 -0.35 Met

Mar. 31 2024 -0.41 -0.38 Beat

Dec. 31 2023 -0.45 -0.43 Beat